Excellence (NICE) guidelines recommend combined mechanical and pharmacological prophylaxis to reduce the risk of venous thromboembolism (VTE) in patients undergoing orthopaedic surgery. There is increasing evidence that anti-embolic stockings (AES) have little effect on reducing such risk. Articles in the MEDLINE, EMBASE, and Cochrane Library were reviewed. Studies on the use of pharmacological prophylaxis recommended in the 2010 NICE guidelines including low-molecular-weight heparin, unfractionated heparin, rivaroxaban, and dabigatran with and without AES in patients undergoing orthopaedic surgery were included. A total of 1171 trauma and elective orthopaedic patients in 4 studies were included; 587 received pharmacological prophylaxis alone, and 584 received a combination of pharmacological prophylaxis and above-or belowknee AES. Of the respective patients, 44 (7.5%) and 31 (5.3%) developed deep vein thrombosis (p=0.1587)
In the absence of any prophylaxis, the incidence of deep vein thrombosis (DVT) is 40 to 70% and of fatal pulmonary embolism (PE) is 1 to 7%. 2, 3 The total cost of their management in the UK is estimated to be around £640 million. 4 In 8000 total hip replacements (THR) performed in 1962 to 1973, the prevalence of PE was 7.89% and of fatal PE was 1.04%. 5 In 2000 THR patients given warfarin for 5 days, bed rest for one week and discharged at 3 weeks, the prevalence of PE was 2.2%. 6 In a subset of 62 patients receiving no prophylactic anticoagulation, it was 3.4%. 6 The mean operating time was 2.4 hours, the mean blood loss was 1.6 litres, and the mean volume of blood transfused was 1.1 litres. 6 Advances have been made in anaesthetic and operative techniques, peri-operative care, and the understanding of the pathophysiology and prevention of VTE. The prevalence of fatal PE decreased to 0.5% in the absence of prophylactic anticoagulation. 7 Combining thromboprophylaxis with an expeditious operation and early mobilisation, the rate has further decreased to <0.18%. 8 In a meta-analysis of major elective and emergency orthopaedic cases, the use of UFH or LMWH reduced the relative risk for DVT by 68% and for PE by 43%. 9 For AES to be effective, they must exert a gradient of pressure to the legs, decreasing from the ankle to the knee (and thigh). A stocking profile of 18 mm Hg at the ankle, 14 mm Hg at the calf and 8 mm Hg at the thigh aids blood flow velocity and promotes 75% of venous return. 10 Few of the commercially available AES deliver the gold standard Sigel profile, and some even created adverse reversed pressure gradients. 11, 12 They are contraindicated in patients with peripheral vascular disease or swollen limbs. AES should be correctly sized and fitted, and inspected 2 to 3 times a day to check for formation of pressure sores. 1 AES are poorly tolerated by patients and incur significant costs.
Whether AES confer additional benefit against VTE when combined with a pharmacological agent remains controversial. 13, 14 The Scottish Intercollegiate Guidelines Network advises against the use of AES due to insufficient evidence, and they are infrequently used in Scotland. 15 This study reviewed the literature to determine whether AES further reduce VTE events in patients undergoing orthopaedic surgery when used in combination with pharmacological agents recommended by the NICE.
Materials and Methods
Articles in the Cochrane Central Register of Controlled Trails, MEDLINE, EMBASE, and referenced in the NICE guidelines were reviewed. Studies on the use of pharmacological prophylaxis recommended in the 2010 NICE guidelines including LMWH, UFH, rivaroxaban, and dabigatran with and without AES in patients undergoing orthopaedic surgery were included. The rates of symptomatic and asymptomatic DVT, PE, and VTE-related death in the 2 groups were compared using the 2-tailed Chisquared test with Yate's correction.
results
A total of 1171 trauma and elective orthopaedic patients in 4 studies were included 14, [16] [17] [18] ; 587 received pharmacological prophylaxis alone and 584 received a combination of pharmacological prophylaxis and above-or below-knee AES. Of the respective patients, 44 (7.5%) and 31 (5.3%) developed DVT (p=0.1587) and 7 (1.2%) and 9 (1.5%) developed PE (p=0.8493) [Table] . The overall VTE rates did not differ significantly (p=0.2864). No death from VTE was reported. Differences between above-and below- Anti-embolism stockings 363 knee AES or between different AES types were not significant.
discussion
Addition of AES did not confer significant reduction in rates of DVT/PE or VTE-related morbidity and mortality in orthopaedic patients, when used in combination with pharmacological agents. AES are recommended for all orthopaedic surgical patients without contraindications, and are used by 70% of all patients in the UK. 1 However, compliance can be a problem and they can cause complications such as skin marking, blistering, ulceration, pain, discomfort, and even limb ischaemia. 19 AES are time-consuming to size and fit, and often do not provide the correct pressure profile, apart from being generally disliked by patients who prefer parenteral anticoagulation. 20, 21 Seven studies were excluded from analysis because they entailed pharmacological agents not recommended in the NICE guidelines; 5 of these involved dextran 70, [22] [23] [24] [25] [26] one involved hypotensive anaesthesia, 16 and one involved dihydroergotamine. 27 Although there were 1171 patients in the 4 studies included; 856 (73%) of them were from a single study. 14 Thus, the power in the remaining articles was weak. Moreover, the evidence of the NICE guidelines is mainly gained from general surgical, obstetrics and gynaecology, and general medical patients rather than the orthopaedic specialty.
In this review, most DVTs were not symptomatic. Asymptomatic DVT detected by ultrasonography or venography has a good prognosis and there is minimal evidence of post-thrombotic syndrome or haemodynamic venous dysfunction. 28 Most patients with DVT and/or PE are asymptomatic. 28 Duplex ultrasonography has high sensitivity (98.7%) and specificity (100%) for detecting DVT. 29 Nonetheless, venography remains the gold standard for diagnosing DVT in the lower extremities. 30 Of 2592 patients undergoing total hip replacement, 10.3% were detected to have DVT by venography and 1% were detected to have PE by ventilation/perfusion scanning. 31 11 of 15 patients diagnosed with in-hospital PE underwent venography; only 3 of whom had a positive scan; 10 of 11 patients with late (at 3 months) PE underwent venography and all were negative. 31 Thus, the benefit of attempting to prevent DVT and PE after total hip or total knee replacement is questionable. 32 In this review, the rate of symptomatic PE and VTE-related mortality in those with or without AES were not significantly different. In a meta analysis of 100 000 patients having joint replacement over the last 15 years, mortality caused by VTE has not decreased with routine thromboprophylaxis. 33 Thus, the benefit of routine thromboprophylaxis after orthopaedic surgery is questionable.
In the CLOTS 1 trial involving 2518 patients with acute stroke, 10% and 10.5% of those fitted with and without compression stockings, respectively, were detected to have DVT by Doppler ultrasonography within 30 days; the absolute risk reduction was 0.5% (not significant). 34 Compression stockings did not affect PE, VTE, and mortality rates, but complications such as skin breaks, ulcers, and skin necrosis were significantly more common. 34 The relatively small number of patients was powered to detect 4% absolute risk reduction, and compliance in the use of stockings fell off with time. 34 The average cost for a pair of knee-length stockings is £3.13, and the number of patients having orthopaedic procedures in the region is 12 000 per year. This yields a total estimated cost of £27 000 (assuming 70% uptake). In 2012, our hospital trust purchased 21 776 knee-length stockings at a cost of £68 158, which is a large part of the hospital budget. Further studies are needed to look into the costeffectiveness of the addition of AES in combination with routine pharmacological thromboprophylaxis for orthopaedic patients.
disclosure
No conflicts of interest were declared by the authors.
